Eliciting hyperacute xenograft response to treat human cancer: α(1,3)galactosyltransferase gene therapy

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2301-2308

  Link Jr , Charles J ^a,b   Seregina, Tatiana ^a   Atchison, Randy ^a   Hall, Allison ^a   Muldoon, Rebecca ^a   Levy, John P ^a  

^a Iowa Cancer Research Foundation   (United States)

^b Iowa Health System   (United States)

Author keywords

(1,3)galactosyltransferase; Complement; Gene therapy; Hyperacute rejection; Retroviral vector

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; GALACTOSYLTRANSFERASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; MELANOMA CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; TUMOR XENOGRAFT;

3T3 CELLS; ANIMALS; BLOOD; BREAST NEOPLASMS; CELL LINE; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CLONING, MOLECULAR; FEMALE; FLOW CYTOMETRY; GALACTOSYLTRANSFERASES; HUMANS; MELANOMA; MICE; MICE, NUDE; OVARIAN NEOPLASMS; RECOMBINANT PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 15644376648     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Sandrin MS and McKenzie IF: Gal alpha (1,3)Gal, the major xenoantigen(s) recognised in pigs by human natural antibodies. Immunol Rev 141: 169-90, 1994.
2. Galili U: Evolution and pathophysiology of the human natural anti-y-galactosyl IgG (anti-Gal) antibody. Springer Semin Immunopathol 15: 155-171, 1993.
3. Platt JL, Vercellotti GM, Dalmasso AP, Matas AJ, Bolman RM, Najarian JS, and Bach FH: Transplantation of discordant xenografts: a review of progress. Immunol. Today 17: 450-457, 1990.
4. Pruitt SK, Kirk AD, Bollinger RR, Marsh J, Henry C., Collins BH, Levin JL, Mault JR, Heinle JS, Ibrahim S, Rudolph AR, Baldwin I, William M., and Sanfilippo F: The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 57: 363-370, 1994.
5. Larsen RD, Rivera-Marrero CA, Ernst LK, Cummings RD, and Lowe JB: Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal:beta-D-Gal(1,4)-D-G1cNAc alpha(1,3)-galactosyltransferase cDNA. J Biol Chem 265: 7055-7061, 1990.
6. Welsh RM, Cooper NR, Jensen FC, and Oldstone MB: Human serum lyses RNA tumor viruses. Nature 257: 612-614, 1975.
7. Rother RP, Squinto SP, Mason JM, and Rollins SA: Protection of retroviral vector particles in human blood through complement inhibition. Hum Gene Ther 6: 429-435, 1995.
8. Takeuchi Y, Porter CD, Strahan KM, Preece AF, Gustafsson K, Cosset FL, Weiss RA, and Collins MK: Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature 379: 85-88, 1996.
9. Rollins SA, Birks CW, Setter E, Squinto SP, and Rother RP: Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: Strategies for evading the humoral immune response. Human Gene Therapy 7: 619-626, 1996.
10. Link CJ, Jr., Moorman D, Seregina T, Levy JP, and Schabold KJ: A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Hum Gene Ther 7: 1161-1179, 1996.
11. Link CJ, Levy JP, Seregina T, Atchinson R, and Moorman D: Protection of complement mediated lysis of murine vector producer cells by sCR1 and low molecular weight heparins. In: Cancer Gene Therapy H. Mazarakis and S. J. Swart (eds.)., pp. 135-152. London, United Kingdom: IBC Library Series, 1997.
12. Gibb AL, Freeman AM, Smith RA, Edmonds S, and Sim E: The interaction of soluble human complement receptor type 1 (sCR1, BRL55730) with human complement component C4. Biochim Biophys Acta 1180: 313-320, 1993.
13. Squinito SP, Rollins SA, Springhorn JP, Fodor WL, and Rother RP: Injectable retroviral particles for human gene therapy. Adv Drug Deivery Rev 17: 213-226, 1995.
14. Larsen RD, Rajan VP, Ruff MM, Kukowska-Latallo J, Cummings RD, and Lowe JB: Isolation of a cDNA encoding a murine UDPgalactose:beta-D-galactosyl-1,4-N-acetyl-D-glucosaminide alpha-1,3-galactosyltransferase: expression cloning by gene transfer. Proc Natl Acad Sci U.S.A. 86: 8227-8231, 1989.
15. Miller AD and Buttimore C: Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Molec. Cell Biol 6: 2895-2902, 1986.
16. Giard D, Aaronson SA, Todaro GJ, Arnestein P, Kersey JH, Dosik H, and Parks WP: In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1973.
17. Bernard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E, and Riou G: Characterization of a human ovarian adenocarcinoma line, IGROV 1, in tissue culture and in nude mice. Cancer Res 45: 4970-4979, 1985.
18. Levy JP, Muldoon RR, Zolotukin S, and Link CJ: Retroviral transfer and expression of humanized, red shifted green fluorescent protein into human tumor cells. Nature Biotechnol 14: 610-614, 1996.
19. Muldoon RR, Levy JP, Kain SR, Kitts PA, and Link CJ: Tracking and quantitation of retroviral mediated transfer using a humanized, red shifted green fluorescent protein gene. BioTechniques 22: 162-167, 1997.
20. Gorelik E, Duty L, Anaraki F, and Galili U: Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by alpha 1,3 galactosyltransferase gene transfection. Cancer Res 55: 4168-4173, 1995.
21. Short MP, Choi BC, Lee JK, Malick A, Breakefield XO, and Martuza RL: Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res 27: 427-439, 1990.
22. Galili U, Shohet SB, Kobrin E, Stults CL, and Macher BA: Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem 263: 17755-17762, 1988.
23. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, and McLeod Griffiss J: Interaction between Human Natural Anti-a-Galactosyl Immunoglobulin G and Bacteria of the Human Flora. Infection and Immunity 56: 1730-1737, 1988.
24. Galili U, Rachmilewitz EA, Pelie A, and Flechner I: A Unique Natural Human IgG Antibody with Anti-a-Galactosyl Specificity. J Exp Med 160: 1519-1531, 1984.
25. Towbin H, Rosenfelder G, Weislander J, Avila JL, Rojas M, Szarfman A, Esser K, Nowack H, and Timple R: Circulating antibodies to mouse laminin in Chagas disease, American cutaneous leishmaniasis and normal individuals recognize terminal galactosyl (a1-3) galactose epitopes. J Exp Med 166: 419, 1987.
26. Almeida IC, Milani SR, Gorin PA, and Travassos LR: Complement-Mediated Lysis of Trypanosoma cruzi Trypomastigotes by Human Anti-a-Galactosyl Antibodies. J of Immunol 146: 2394-2400, 1991.
27. Galili U and Latemple DC: Natural anti-gal antibody as a universal augmentor of autologous tumor vaccine immunogenicity. Immunol Today 18: 281-285, 1997.
28. Thall AD, Murphy HS, and Lowe JB: alpha 1,3-Galactosyltransferase-deficient mice produce naturally occurring cytotoxic anti-Gal antibodies. Transplant Proc 28: 556-557, 1996.
29. Tange M, Tearle R, Katerelos M, Crawford R, Robins A, Shinkel T, Pearse M, and d'Apice AJ: Analysis of alpha 1,3-galactosyltransferase knockout mice. Transplant Proc 28: 620-621, 1996.